Highlights

  • CSL is targeting FY27 underlying NPAT growth of approximately 5%, with Revenue expected to be broadly in line with FY26.
  • CSL Behring is expected to deliver mid-single-digit revenue growth, with immunoglobulin sales anticipated to grow at a mid-to-high single-digit rate.
  • Vifor’s outlook is a headwind, with revenue guided to decline around 25% due to generic competition and the end of certain regulatory protections.
  • CSL has announced a further A$1.1 billion share buy-back and plans to invest approximately US$1.5 billion in expanding its US plasma Manufacturing footprint.

CSL Limited (ASX:CSL) has described FY26 as a “reset year,” and the company’s FY27 outlook is effectively the test of that reset. After absorbing large Impairment and restructuring charges, CSL is now guiding toward a return to Earnings growth, with the trajectory of its core businesses — Behring, Seqirus and Vifor — set to determine how that plays out.

FY27 Guidance Points to a Return to Growth

CSL expects FY27 revenue to be broadly in line with FY26 and underlying NPAT to grow by approximately 5%, using FY26 exchange rates. That guidance implies the heavy impairment and restructuring charges recognised in FY26 were largely one-off in nature, with the underlying Business expected to resume its growth path.

Behring’s Immunoglobulin Franchise Is the Swing Factor

CSL Behring, the group’s largest business, is expected to deliver mid-single-digit revenue growth in FY27, with immunoglobulin revenue — its biggest product category — anticipated to grow at a mid-to-high single-digit rate. Newer therapies including ANDEMBRY and HEMGENIX are expected to keep contributing to growth, offsetting continued softness in the legacy FVIII portfolio and pricing pressure on KCENTRA.

Vifor Faces a Structural Headwind

The clearest risk to the outlook sits within CSL Vifor, where revenue is guided to decline by approximately 25% in FY27. That reflects generic competition in iron products, the conclusion of VELPHORO’s TDAPA period and the revocation of TAVNEOS’s Marketing authorisation — all structural rather than cyclical factors that will need to be offset by growth elsewhere in the portfolio.

Investment in Plasma and Cost Transformation Continue

CSL is continuing to invest for the next stage of growth, including approximately US$1.5 billion earmarked for expanding its US plasma manufacturing footprint and the Horizon 2 Yield improvement program. The company’s transformation program delivered roughly US$176 million of cost savings in FY26 and remains an ongoing lever for Margin recovery. Shareholders are also being supported through a further A$1.1 billion buy-back and a maintained dividend.

What to Watch

Investors will be watching whether Behring’s immunoglobulin growth and newer therapy sales are enough to offset Vifor’s decline and continued Seqirus softness. Progress on the transformation program’s cost savings and the pace of the US plasma Investment will also be relevant markers of execution against FY27 guidance.

Conclusion

CSL’s outlook for FY27 centres on whether its core Behring franchise can outweigh a structurally shrinking Vifor business and deliver on the company’s guided 5% underlying NPAT growth. Continued investment in plasma capacity and cost transformation, alongside ongoing Capital returns, form the backdrop against which that growth target will be tested.